Future directions of acute ischaemic stroke therapy

The Lancet Neurology

Volumn 14, Issue 7, 2015, Pages 758-767

  Fisher, Marc ^a,b   Saver, Jeffrey L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DESMOTEPLASE; LIPOCORTIN 2; TENECTEPLASE; FIBRINOLYTIC AGENTS; TISSUE PLASMINOGEN ACTIVATOR;

ANTICOAGULANT THERAPY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY RECANALIZATION; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEALTH CARE DELIVERY; HUMAN; IMAGE ANALYSIS; MANAGED CARE; MECHANICAL THROMBECTOMY; META ANALYSIS (TOPIC); MULTIMODAL IMAGING; NEUROIMAGING; NEUROPROTECTION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SELECTION; PERFUSION WEIGHTED IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); FORECASTING; HUMANS; MAGNETIC RESONANCE IMAGING; STROKE; THROMBOLYTIC THERAPY; TRENDS;

BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; FORECASTING; HUMANS; MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84930508748     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00054-X     Document Type: Note

References (84)

1. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1587. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
2. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012, 379:2364-2372.
3. Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012, 379:2352-2363. the IST-3 collaborative group.
4. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329. the ECASS Investigators.
5. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013, 309:2480-2488.
6. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and, stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014, 384:1929-1935. the Stroke Thrombolysis Trialists' Collaborative Group.
7. Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013, 44:870-947. the American Heart Association Stroke Council, the Council on Cardiovascular Nursingthe Council on Cardiovascular Nursing, the Council on Peripheral Vascular Diseasethe Council on Peripheral Vascular Disease, the Council on Clinical Cardiologythe Council on Clinical Cardiology.
8. Wechsler LR, Jovin TG Intravenous recombinant tissue-type plasminogen activator in the extended time window and the US Food and Drug Administration: confused about the time. Stroke 2012, 43:2517-2519.
9. Turk AS, Frei D, Fiorella D, et al. ADAPT FAST study: a direct aspiration first pass technique for acute stroke thrombectomy. J Neurointerv Surg 2014, 6:260-264.
10. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005, 36:1432-1438. the MERCI Trial Investigators.
11. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009, 40:2761-2768. Penumbra Pivotal Stroke Trial Investigators.
12. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013, 368:893-903. the Interventional Management of Stroke (IMS) III Investigators.
13. Ciccone A, Valvassori L, Nichelatti M, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013, 368:904-913. the SYNTHESIS Expansion Investigators.
14. Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013, 368:914-923. the MR RESCUE Investigators.
15. Nogueira RG, Lutsep HL, Gupta R, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012, 380:1231-1240. the TREVO 2 Trialists.
16. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012, 380:1241-1249. the SWIFT Trialists.
17. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015, 372:11-20. the MR CLEAN Investigators.
18. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015, 372:1019-1030. the ESCAPE Trial Investigators.
19. Campbell BCV, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015, 372:1009-1018. the EXTEND-IA Investigators.
20. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs t-PA alone in stroke. N Engl J Med 2015, published online April 17. 10.1056/NEJMoa1415061.
21. Jovin TG, Chamorro A, Cobo A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015, published online April 17. 10.1056/NEJMoa1503780.
22. Asplund K, Glader EL, Norrving B, Erikson M Effects of extending the time window of thrombolysis to 4·5 hours: observations in the Swedish Stroke Register (Riks-Stroke). Stroke 2011, 42:2492-2497. the Riks-Stroke Collaboration.
23. Hunter RM, Davie C, Rudd A, et al. Impact on clinical and cost outcomes of a centralized approach to acute stroke care in London: a comparative effectiveness before and after model. PLoS ONE 2013, 8:e70420.
24. Fisher M, Albers GW Advanced imaging to extend the therapeutic time window of acute ischemic stroke. Ann Neurol 2013, 73:4-9.
25. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006, 60:508-517. the DEFUSE Investigators.
26. Lansberg MG, Straka M, Kemp S, et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol 2012, 11:860-867. the DEFUSE 2 study investigators.
27. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008, 7:299-309. the EPITHET investigators.
28. Yoo AJ, Verduzco LA, Schaefer PW, Hirsch JA, Rabinov JD, González RG MRI-based selection for intra-arterial stroke therapy: value of pretreatment diffusion-weighted imaging lesion volume in selecting patients with acute stroke who will benefit from early recanalization. Stroke 2009, 40:2046-2054.
29. Nagakane Y, Christensen S, Brekenfeld C, et al. EPITHET: Positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke 2011, 42:59-64. the EPITHET Investigators.
30. Labeyrie MA, Turc G, Hess A, et al. Diffusion lesion reversal after thrombolysis: a MR correlate of early neurological improvement. Stroke 2012, 43:2986-2991.
31. Thomalla G, Cheng B, Ebinger M, et al. DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol 2011, 10:978-986. the STIR and VISTA Imaging Investigators.
32. González RG, Lev MH, Goldmacher GV, et al. Improved outcome prediction using CT angiography in addition to standard ischemic stroke assessment: results from the STOPStroke study. PLoS ONE 2012, 7:e30352.
33. Wintermark M, Flanders AE, Velthuis B, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006, 37:979-985.
34. Campbell BC, Christensen S, Levi CR, et al. Cerebral blood flow is the optimal CT perfusion parameter for assessing infarct core. Stroke 2011, 42:3435-3440.
35. De Silva DA, Churilov L, Olivot JM, et al. Greater effect of stroke thrombolysis in the presence of arterial obstruction. Ann Neurol 2011, 70:601-605. the EPITHET-DEFUSE Investigators.
36. Lin L, Bivard A, Levi CR, Parsons MW Comparison of computed tomographic and magnetic resonance perfusion measurements in acute ischemic stroke: back-to-back quantitative analysis. Stroke 2014, 45:1727-1732.
37. Ebinger M, Grittner U, Audebert HJ Ambulance-based thrombolysis in acute ischemic stroke-reply. JAMA 2014, 312:961-962.
38. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology 2012, 79:306-313.
39. Appelros P, Jonsson F, Åsberg S, et al. Trends in stroke treatment and outcome between 1995 and 2010: observations from Riks-Stroke, the Swedish stroke register. Cerebrovasc Dis 2014, 37:22-29. the Riks-Stroke Collaboration.
40. Goyal M, Menon BK, Hill MD, Demchuk A Consistently achieving computed tomography to endovascular recanalization <90 minutes: solutions and innovations. Stroke 2014, 45:e252-e256.
41. Fisher M The ischemic penumbra: a new opportunity for neuroprotection. Cerebrovasc Dis 2006, 21(suppl 2):64-70.
42. Saver JL Time is brain-quantified. Stroke 2006, 37:263-266.
43. Henninger N, Bratane BT, Bastan B, Bouley J, Fisher M Normobaric hyperoxia and delayed tPA treatment in a rat embolic stroke model. J Cereb Blood Flow Metab 2009, 29:119-129.
44. Bråtane BT, Cui H, Cook DJ, Bouley J, Tymianski M, Fisher M Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor. Stroke 2011, 42:3265-3270.
45. Yenari MA, Onley D, Hedehus M, et al. Diffusion- and perfusion-weighted magnetic resonance imaging of focal cerebral ischemia and cortical spreading depression under conditions of mild hypothermia. Brain Res 2000, 885:208-219.
46. Saver JL, Starkman S, Eckstein M, et al. Methodology of the Field Administration of Stroke Therapy- Magnesium (FAST-MAG) phase 3 trial: Part 2-prehospital study methods. Int J Stroke 2014, 9:220-225. the FAST-MAG Investigators and Coordinators.
47. Iadecola C, Anrather J The immunology of stroke: from mechanisms to translation. Nat Med 2011, 17:796-808.
48. Sanderson TH, Reynolds CA, Kumar R, Przyklenk K, Hüttemann M Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Mol Neurobiol 2013, 47:9-23.
49. Hausenloy DJ, Yellon DM Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 2013, 123:92-100.
50. Bhatia R, Hill MD, Shobha N, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke 2010, 41:2254-2258.
51. Guerrero WR, Grotta JC Defining intravenous recombinant tissue plasminogen activator failure. Stroke 2013, 44:819-821.
52. Fiebach JB, Al-Rawi Y, Wintermark M, et al. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 2012, 43:1561-1566.
53. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005, 36:66-73. the DIAS Study Group.
54. Albers GW, von Kummer R, Trulsen T, et al. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol 2015, 14:575-584.
55. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006, 37:1227-1231. the DEDAS Investigators.
56. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009, 8:141-150.
57. Behrouz R Intravenous tenecteplase in acute ischemic stroke: an updated review. J Neurol 2014, 261:1069-1072.
58. Haley EC, Thompson JL, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010, 41:707-711. the Tenecteplase in Stroke Investigators.
59. Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012, 366:1099-1107.
60. Barreto AD, Alexandrov AV, Lyden P, et al. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke 2012, 43:770-775.
61. Fan X, Yu Z, Liu J, et al. Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy. Stroke 2010, 41(suppl):S54-S58.
62. Zhu H, Fan X, Yu Z, et al. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab 2010, 30:1137-1146.
63. Walvick RP, Bråtane BT, Henninger N, et al. Visualization of clot lysis in a rat embolic stroke model: application to comparative lytic efficacy. Stroke 2011, 42:1110-1115.
64. Meairs S, Alonso A, Hennerici MG Progress in sonothrombolysis for the treatment of stroke. Stroke 2012, 43:1706-1710.
65. Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004, 351:2170-2178. the CLOTBUST Investigators.
66. Saqqur M, Tsivgoulis G, Nicoli F, et al. The role of sonolysis and sonothrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and case-control studies. J Neuroimaging 2014, 24:209-220.
67. Walter S, Kostopoulos P, Haass A, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol 2012, 11:397-404.
68. Ebinger M, Winter B, Wendt M, et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA 2014, 311:1622-1631. the STEMO Consortium.
69. Domínguez C, Delgado P, Vilches A, et al. Oxidative stress after thrombolysis-induced reperfusion in human stroke. Stroke 2010, 41:653-660.
70. Rha J-H, Saver JL Recanalization as a surrogate outcome measure in thrombolytic clinical trials: A meta-analysis. Stroke 2003, 34:317. (abstract).
71. Califf RM Evaluation of diagnostic imaging technologies and therapeutics devices: better information for better decisions: proceedings of a multidisciplinary workshop. Am Heart J 2006, 152:50-58. the Workshop Participants.
72. Saver JL, Jovin TG, Smith WS, et al. Stroke treatment academic industry roundtable: research priorities in the assessment of neurothrombectomy devices. Stroke 2013, 44:3596-3601. the STAIR VIII Consortium.
73. Ali M, Bath P, Brady M, et al. Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses. Int J Stroke 2012, 7:133-138. the VISTA Steering Committees.
74. Krumholz HM, Peterson ED Open access to clinical trials data. JAMA 2014, 312:1002-1003.
75. Chaisinanunkul NN, Starkman S, Gornbein JA, et al. Assessing disability outcome in acute stroke clinical trials: Increased study power with linear (ALDS) compared with ordinal (MRS) scales. Stroke 2014, 45:A138.
76. Rose M, Bjorner JB, Gandek B, Bruce B, Fries JF, Ware JE The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiency. J Clin Epidemiol 2014, 67:516-526.
77. Saver JL Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices. Stroke 2011, 42:2356-2362.
78. Bath PM, Lees KR, Schellinger PD, et al. Statistical analysis of the primary outcome in acute stroke trials. Stroke 2012, 43:1171-1178. the European Stroke Organisation Outcomes Working Group.
79. Whiteley WN, Thompson D, Murray G, et al. Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (third International Stroke Trial). Stroke 2014, 45:3612-3617. the IST-3 Collaborative Group.
80. Kakuda W, Lansberg MG, Thijs VN, et al. Optimal definition for PWI/DWI mismatch in acute ischemic stroke patients. J Cereb Blood Flow Metab 2008, 28:887-891. the DEFUSE Investigators.
81. Alberts MJ, Latchaw RE, Selman WR, et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke 2005, 36:1597-1616. the Brain Attack Coalition.
82. Saver J, Levy E, McDougall C, et al. Planning for nationwide endovascular acute ischemic stroke care in the united states: Report of the interventional stroke workforce study group. The Stroke Interventionalist 2012, 1.
83. Higashida R, Alberts MJ, Alexander DN, et al. Interactions within stroke systems of care: a policy statement from the American Heart Association/American Stroke Association. Stroke 2013, 44:2961-2984. the American Heart Association Advocacy Coordinating Committee.
84. Nazliel B, Starkman S, Liebeskind DS, et al. A brief prehospital stroke severity scale identifies ischemic stroke patients harboring persisting large arterial occlusions. Stroke 2008, 39:2264-2267.